Global Liposarcoma Market - 2023-2030

Overview

The liposarcoma market is experiencing steady growth in recent years owing to the increasing prevalence and rising awareness. Liposarcoma typically affects more men and people assigned male at birth (AMAB) than women and people assigned female at birth (AFAB). It is often found in men and people AMAB between ages 50 and 65, but one type of liposarcoma affects people ages 35 to 55.

Liposarcomas mainly arise from the lipocytes found in soft tissues. The cause of liposarcoma is still unknown. The treatment options include surgery, radiation therapy, chemotherapy, and the other choice of treatment depending on factors such as tumor size, location, and stage. Moreover, targeted therapies and immunotherapies are being explored in clinical trials with better and improved treatment outcomes.

Owing to the rising prevalence of liposarcoma, increasing demand for minimally invasive treatment options, an increasing number of clinical trials, increasing adoption of immunotherapy for better treatment, early detection and diagnosis, increasing demand for novel drugs for liposarcoma treatment, and technological advancements in diagnosis and treatment options are the major factors expected to drive the global liposarcoma market over the forecast period.

Dynamics

Rising Demand for Novel Drugs Drives the Growth of the Liposarcoma Market

The increasing prevalence of liposarcoma leads to increasing demand for better treatment options. Moreover, growing awareness in the public about this rare cancer has led to earlier diagnosis and increased demand for advanced treatment approaches. Due to the rarity of liposarcoma, there are very limited treatment options, so there is a rising demand for novel drugs with enhanced and better results. This demand for improved treatments has spurred research and development efforts leading to the discovery and development of new drugs targeting liposarcoma.

Currently, available treatment options for liposarcoma like surgical therapy, radiation therapy, and chemotherapy, targeted therapy have limitations, mainly in advanced cases. Patients with this type of cancer are seeking new treatment options that can provide better outcomes and improved quality of life. Soo the demand for novel drugs with enhanced patient outcomes is continuously increasing for better treatment.

For instance, on March 29, 2022, Australian biotech company Noxopharm announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Veyonda, its lead oncology drug candidate, for use in the treatment of soft tissue sarcoma including liposarcoma.

Increasing Number of Clinical Trials for Liposarcoma Treatment Also Drives the Growth of the Liposarcoma Market

There is an increasing number of clinical trials for liposarcoma that offers an opportunity to explore new treatment options including targeted therapies, immunotherapies, and other combination drugs for the liposarcoma treatment. These enhanced clinical trials are crucial in identifying risk factors and expanding the treatment options for this rare type of cancer.

For instance, in July 2023, the Brightline-1 clinical trial program progressed to Phase III and the European Medicines Agency granted brigimadlin (BI 907828) Orphan Drug Designation for the potential treatment of soft tissue sarcoma, including dedifferentiated liposarcoma (DDLS). Both milestones are promising steps towards delivering meaningful advances for the treatment of this rare and aggressive form of sarcoma.

Limited Treatment Options Will Hamper the Growth of the Market

There are limited treatment options available for liposarcoma, and the availability of only a few treatment modalities for leads to reduced patient outcomes. The patient's response to treatment is different based on tumor characteristics, tumor stage, and having limited options reduces the patient outcomes.

Moreover, the lack of enhanced treatment options may limit the flexibility of healthcare providers in providing treatment plans for each and every patient. Personalized treatment approaches can leads to more effective and patient-specific care resulting in enhanced patient outcomes.

The limited treatment options also reduce the research activities and clinical trials due to the less competition in the market. The availability of limited treatment options also impacts the cost, they may be available at unaffordable costs.

Segment Analysis

The global liposarcoma market is segmented based on type, treatment type, end-user, and region.

Well-differentiated liposarcoma (WDLS) from Type Segment Accounts for 38.6% of the Liposarcoma Market Share

The well-differentiated liposarcoma is the most common type, incidence is approximately 1 in 200,000 per year and accounts for 30% to 50% of all liposarcomas. These are slow-growing painless tumors. They mainly appear in the arms and legs or trunk. This type of liposarcoma is also known as atypical lipomatous tumors. When the liposarcoma is in the back of the abdomen/belly (retroperitoneum), it's called a well-differentiated liposarcoma.

Moreover, there are an average of 110 cases of WDLS diagnosed every year in England. WDLS consists of a mature adipocytic proliferation, with marked variation in cell size and at least focal nuclear atypia in fat cells or stromal spindle cells. Fibrous septa are often present and contain hyperchromatic stromal cells. The presence of lipoblasts is not required for a diagnosis of liposarcoma and does not make a diagnosis of liposarcoma, as lipoblasts may be present in some benign tumors.

Geographical Penetration

North America Accounted for Approximately 39.4% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Advanced Healthcare Infrastructure

North America is home to many leading pharmaceutical and biotechnology companies and research universities that are actively engaged in the research, development, clinical trials, and commercialization of liposarcoma treatments. These major players invest significant resources in developing novel therapies and conducting clinical trials, contributing to the availability and accessibility of advanced treatment options in the region. Their prominence in the market enables them to effectively market and distribute their products, further driving market growth.

For instance, on June 20, 2023, the University of Texas MD Anderson Cancer Center and Replay announced that the Food & Drug Administration (FDA) has issued a 'safe to proceed' for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.

North America boasts a well-developed and advanced healthcare infrastructure. Due to the large population in North America, liposarcoma affects 1 in 100,000 people in the U.S. each year. The region's healthcare infrastructure allows for early diagnosis, comprehensive treatment planning, and access to treatment therapies for liposarcoma patients.

Competitive Landscape

The major global players in the liposarcoma market include: Pfizer Inc., Johnson & Johnson., Sanofi SA, Eli Lilly and Company, Novartis AG, Baxter, Teva Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, and GSK Plc among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global liposarcoma market. During the pandemic, many clinical trials and research activities investigating novel liposarcoma treatment options were temporarily suspended or slowed down due to the pandemic related restrictions on patient recruitment, site closures, and redirection of research resources towards COVID-19-related studies. This delayed the development and approval of new treatment therapies.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global liposarcoma market. The pharmaceutical companies which are involved in the production or distribution of liposarcoma treatments have operations or supply chain links in the conflict-affected regions, there could be disruptions in the availability of drugs or medical supplies for patients worldwide leading to an impact on the global liposarcoma treatment market.

By Type

• Well-differentiated liposarcoma (WDLS)
• Myxoid liposarcoma/round cell liposarcoma
• Dedifferentiated liposarcoma (DDLS)
• Pleomorphic liposarcoma

By Treatment Type

• Surgical Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Others

By End-User

• Hospitals
• Specialty Clinics
• Cancer Research Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On February 17, 2023, Specialised Therapeutics (ST), a Singapore-headquartered biopharmaceutical company announced that its portfolio therapy to treat rare soft tissue sarcomas has now been approved in New Zealand. Medsafe has approved the use of YONDELIS (trabectedin) for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen. YONDELIS (trabectedin) is used extensively around the world and has been shown to improve progression-free survival.

Why Purchase the Report?

• To visualize the global liposarcoma market segmentation based on type, treatment type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of liposarcoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global liposarcoma market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies